Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Net Cash Flow: 2015-2024

Historic Net Cash Flow for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to -$3.9 million.

  • Corvus Pharmaceuticals' Net Cash Flow fell 16.37% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 96.04%. This contributed to the annual value of -$3.9 million for FY2024, which is 619.85% down from last year.
  • As of FY2024, Corvus Pharmaceuticals' Net Cash Flow stood at -$3.9 million, which was down 619.85% from -$539,000 recorded in FY2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Net Cash Flow peaked at $47.0 million during FY2021, and registered a low of -$50.3 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$3.9 million (2024), whereas its average is -$18.2 million.
  • In the last 5 years, Corvus Pharmaceuticals' Net Cash Flow surged by 315.92% in 2021 and then plummeted by 619.85% in 2024.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Net Cash Flow stood at $11.3 million in 2020, then surged by 315.92% to $47.0 million in 2021, then plummeted by 207.01% to -$50.3 million in 2022, then spiked by 98.93% to -$539,000 in 2023, then tumbled by 619.85% to -$3.9 million in 2024.